Viome Raises $86.5M in Series C Funding to Pioneer the Future of Personalized Health and Wellness

Viome, a Viome Life Sciences, Inc. company, is excited to announce that it has secured $86,500,000 in its latest funding round—a pivotal milestone that will accelerate our mission to transform healthcare. As the industry’s only direct-to-consumer healthcare test that analyzes both microbial and human gene expressions (mRNA), our innovative solutions—developed through over a decade of scientific research and exclusively licensed technology from Los Alamos National Lab—enable individuals to gain unprecedented insights into their health and nutrition. This significant investment is a strong vote of confidence in our pioneering approach and will be used to further develop our state-of-the-art testing technology, expand our research capabilities, and enhance our personalized, adaptive wellness recommendations. With this funding, Viome is uniquely positioned to extend our direct-to-consumer model even further, empowering individuals to take proactive control over their health. By creating a comprehensive profile of your unique biochemistry and ecosystem, our technology ensures that you receive health insights and nutritional guidance tailored specifically to your body’s changing needs. Our at-home tests serve not merely as one-time screenings, but as continuous health companions that monitor and adapt to your evolving lifestyle, making wellness a matter of choice instead of mere chance. The financial backing will also help us invest in further scaling our team of scientists, engineers, researchers, and entrepreneurs—all united by a passion for radically improving the wellness of our customers. Join us in this revolutionary movement where enhanced longevity and vitality are within everyone’s reach.